GRADUATE NURSING • ADVANCED PHARMACOLOGY
NUR 635 FINAL EXAM 1 GCU
2026/2027 LATEST VERSION
WITH ACTUAL EXAM QUESTIONS
AND 100% CORRECT ANSWERS A+
GRADED A+
NUR 635 Advanced Pharmacology Actual Final Exam 2026/2027 (Brand New!!)
A+ QUESTIONS 5 SECTIONS 100%
VERIFIED COMPLETE RATIONALES
CATEGORIES
Pharmacokinetics & Pharmacodynamics
Cardiovascular & Renal Agents
Anti-infectives & Antimicrobial Stewardship
CNS, Psychotropics & Pain Management
Endocrine, Respiratory & Special Populations
EXAM STRUCTURE
• Questions aligned to graduate-level advanced pharmacology competencies
• Emphasis on mechanism, clinical application, safety, and monitoring
• Each item includes a verified correct answer and a concise rationale
• Designed for final-exam style self-assessment
• Passing benchmark: 80%
STUVIAACTUALEXAM
, SECTION 1: Pharmacokinetics & Pharmacodynamics
Q1.
A 68-year-old patient with reduced hepatic blood flow is started on a drug that undergoes extensive first-pass metabolism. The advanced practice
nurse anticipates that the oral bioavailability of this drug will most likely be
A. decreased because of slower intestinal absorption
B. increased because of reduced first-pass extraction
C. unchanged because first-pass metabolism is independent of blood flow
D. eliminated entirely so that only parenteral routes remain effective
Correct Answer: B
Rationale: Reduced hepatic blood flow decreases the rate of delivery of drug to metabolizing enzymes, often lowering first-pass extraction and thereby increasing oral
bioavailability of high-extraction drugs.
Q2.
A patient taking a drug that is highly bound to plasma albumin develops severe hypoalbuminemia. The most immediate pharmacokinetic
consequence is
A. a permanent decrease in the drug’s volume of distribution
B. complete loss of renal clearance of the drug
C. conversion of the drug from a weak acid to a weak base
D. an increase in the unbound (free) fraction of the drug, potentially intensifying pharmacologic effect
Correct Answer: D
Rationale: Only unbound drug is pharmacologically active and available for distribution and clearance. A sudden drop in binding protein raises the free fraction until a
new steady state is reached.
Q3.
A clinician is selecting a loading dose for a drug with a long half-life. The primary purpose of the loading dose is to
A. reduce the total daily maintenance dose by 50 percent
B. rapidly achieve a therapeutic plasma concentration without waiting for multiple half-lives of accumulation
C. eliminate the need for any subsequent maintenance doses
D. prevent all future drug interactions with CYP3A4 substrates
Correct Answer: B
Rationale: Loading doses fill the volume of distribution quickly so that therapeutic levels are reached promptly; maintenance doses then replace drug lost through
clearance.
Q4.
A patient is switched from an immediate-release formulation to an extended-release formulation of the same drug at the same total daily dose. The
expected change in the concentration–time profile is
A. higher peak concentration and complete loss of trough levels
B. identical peak and trough values because total dose is unchanged
C. lower peak concentration and higher trough concentration with reduced fluctuation
D. complete absence of measurable plasma levels for the first 12 hours
Correct Answer: C
Rationale: Extended-release products slow absorption, dampening peaks and raising troughs, which can improve tolerability and adherence while maintaining overall
exposure.
Q5.
A drug that follows nonlinear (Michaelis–Menten) pharmacokinetics is administered at increasing doses. Once elimination pathways approach
saturation, further dose increases will produce
A. strictly proportional increases in plasma concentration
B. a paradoxical decrease in plasma concentration
C. disproportionately large increases in plasma concentration and AUC
D. no change in plasma concentration because clearance rises in parallel
Correct Answer: C
Rationale: When capacity-limited elimination is saturated, clearance declines with rising concentration, so AUC increases more than proportionally to dose.
Q6.
A patient with chronic kidney disease (eGFR 25 mL/min) is prescribed a drug that is eliminated primarily by glomerular filtration. The most
appropriate initial adjustment is to
A. increase the dose to overcome reduced filtration
B. switch exclusively to a hepatically cleared drug without further evaluation
C. administer the drug only by continuous intravenous infusion
D. reduce the dose or extend the dosing interval according to residual renal function
Correct Answer: D
Rationale: Reduced GFR lowers clearance of renally eliminated drugs; dose reduction or interval extension prevents accumulation and toxicity.
NUR 635 FINAL EXAM 1 GCU
2026/2027 LATEST VERSION
WITH ACTUAL EXAM QUESTIONS
AND 100% CORRECT ANSWERS A+
GRADED A+
NUR 635 Advanced Pharmacology Actual Final Exam 2026/2027 (Brand New!!)
A+ QUESTIONS 5 SECTIONS 100%
VERIFIED COMPLETE RATIONALES
CATEGORIES
Pharmacokinetics & Pharmacodynamics
Cardiovascular & Renal Agents
Anti-infectives & Antimicrobial Stewardship
CNS, Psychotropics & Pain Management
Endocrine, Respiratory & Special Populations
EXAM STRUCTURE
• Questions aligned to graduate-level advanced pharmacology competencies
• Emphasis on mechanism, clinical application, safety, and monitoring
• Each item includes a verified correct answer and a concise rationale
• Designed for final-exam style self-assessment
• Passing benchmark: 80%
STUVIAACTUALEXAM
, SECTION 1: Pharmacokinetics & Pharmacodynamics
Q1.
A 68-year-old patient with reduced hepatic blood flow is started on a drug that undergoes extensive first-pass metabolism. The advanced practice
nurse anticipates that the oral bioavailability of this drug will most likely be
A. decreased because of slower intestinal absorption
B. increased because of reduced first-pass extraction
C. unchanged because first-pass metabolism is independent of blood flow
D. eliminated entirely so that only parenteral routes remain effective
Correct Answer: B
Rationale: Reduced hepatic blood flow decreases the rate of delivery of drug to metabolizing enzymes, often lowering first-pass extraction and thereby increasing oral
bioavailability of high-extraction drugs.
Q2.
A patient taking a drug that is highly bound to plasma albumin develops severe hypoalbuminemia. The most immediate pharmacokinetic
consequence is
A. a permanent decrease in the drug’s volume of distribution
B. complete loss of renal clearance of the drug
C. conversion of the drug from a weak acid to a weak base
D. an increase in the unbound (free) fraction of the drug, potentially intensifying pharmacologic effect
Correct Answer: D
Rationale: Only unbound drug is pharmacologically active and available for distribution and clearance. A sudden drop in binding protein raises the free fraction until a
new steady state is reached.
Q3.
A clinician is selecting a loading dose for a drug with a long half-life. The primary purpose of the loading dose is to
A. reduce the total daily maintenance dose by 50 percent
B. rapidly achieve a therapeutic plasma concentration without waiting for multiple half-lives of accumulation
C. eliminate the need for any subsequent maintenance doses
D. prevent all future drug interactions with CYP3A4 substrates
Correct Answer: B
Rationale: Loading doses fill the volume of distribution quickly so that therapeutic levels are reached promptly; maintenance doses then replace drug lost through
clearance.
Q4.
A patient is switched from an immediate-release formulation to an extended-release formulation of the same drug at the same total daily dose. The
expected change in the concentration–time profile is
A. higher peak concentration and complete loss of trough levels
B. identical peak and trough values because total dose is unchanged
C. lower peak concentration and higher trough concentration with reduced fluctuation
D. complete absence of measurable plasma levels for the first 12 hours
Correct Answer: C
Rationale: Extended-release products slow absorption, dampening peaks and raising troughs, which can improve tolerability and adherence while maintaining overall
exposure.
Q5.
A drug that follows nonlinear (Michaelis–Menten) pharmacokinetics is administered at increasing doses. Once elimination pathways approach
saturation, further dose increases will produce
A. strictly proportional increases in plasma concentration
B. a paradoxical decrease in plasma concentration
C. disproportionately large increases in plasma concentration and AUC
D. no change in plasma concentration because clearance rises in parallel
Correct Answer: C
Rationale: When capacity-limited elimination is saturated, clearance declines with rising concentration, so AUC increases more than proportionally to dose.
Q6.
A patient with chronic kidney disease (eGFR 25 mL/min) is prescribed a drug that is eliminated primarily by glomerular filtration. The most
appropriate initial adjustment is to
A. increase the dose to overcome reduced filtration
B. switch exclusively to a hepatically cleared drug without further evaluation
C. administer the drug only by continuous intravenous infusion
D. reduce the dose or extend the dosing interval according to residual renal function
Correct Answer: D
Rationale: Reduced GFR lowers clearance of renally eliminated drugs; dose reduction or interval extension prevents accumulation and toxicity.
